Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
Sindet-Pedersen, Caroline; Langtved Pallisgaard, Jannik; Staerk, Laila; Gerds, Thomas Alexander; Fosbøl, Emil Loldrup; Torp-Pedersen, Christian; Gislason, Gunnar; Olesen, Jonas Bjerring.
; 117(6): 1182-1191, 2017 06 02.
Artigo em Inglês | MEDLINE | ID: mdl-28300865
Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism.
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery.
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Direct Oral Anticoagulants in End-Stage Renal Disease.
Parenteral anticoagulation in ambulatory patients with cancer.
Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
Influence of baseline anemia on long-term clinical outcomes in patients with venous thromboembolism: from the COMMAND VTE registry.
The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy.